Pancreozymin in man as in animals appears to act as a specific enzyme stimulant. The preparations of pancreozymin used in these experiments also contain cholecystokinin, which causes the gall bladder to contract, and a smooth muscle stimulant, possibly substance P.The (Lagerlof, 1939(Lagerlof, , 1942 Diamond, Siegel, Gall, and Karlen, 1939;Diamond andSiegel, 1940, 1941;Comfort and Osterberg, 1940;Pratt, Brugsch, and Rostler, 1940;Pollard, Miller, and Brewer, 1942;Lake, 1947;Dornberger, Comfort, Wollaeger, and Power, 1948;Dreiling and Hollander, 1948, 1950;Friedman and Snape, 1950;Dreiling, 1950Dreiling, , 1951Dreiling, , 1953Dreiling, , 1955 Dreiling and Janowitz, 1957;Wenger and Raskin, 1958).In anaesthetized animals secretin produced a large volume of pancreatic juice of constant alkalinity and low enzyme content. Harper and Raper (1943) isolated from the small intestine a second material, other than secretin, which increased the enzyme output by the pancreas without affecting the volume of juice. This material they named pancreozymin. Crick, Harper, and Raper (1949) later published a revised method of preparing secretin and pancreozymin and preliminary experiments showed that pancreozymin had the same effect on man as in animals

A simple evocative test has been used to study pancreatic function. Serial estimations of amylase and lipase in blood serum are made at intervals up to six hours and again at 24 hours after injecting intravenously standard doses of secretin and pancreozymin. The results of 213 tests on a normal group, in pancreatic disease, in biliary and hepatic diseases have been analysed and compared with the results of duodenal intubation and an oral glucose tolerance test. A combined evocative test and oral glucose tolerance test provide evidence of pancreatic dysfunction in the majority of cases of cancer of the pancreas and chronic pancreatitis. The conditions of the test are described and the pathological lesions in which false positive evocative tests may be found are indicated.The simple evocative test provides the earliest biochemical evidence of pancreatic disease in some patients with cancer of the pancreas and chronic pancreatitis.

No abstract

Peptic secretion was studied in fasting anaesthetized cats in which the pylorus and common bile duct had been occluded to prevent the release of duodenal hormones which might stimulate or inhibit gastric secretion. Dilute acid was instilled into the stomach at intervals to aid recovery of gastric secretion and to preserve peptic activity. 2. Caerulein, histamine and N‐methyl histamine did not increase the output of pepsin when given on their own. Desulphated caerulein was a weak peptic stimulant. 3. Two C.H.R. u./kg per hour secretin initiated pancreatic secretion, the volume of which increased progressively as the dose was increased by stages to 32 C.H.R. u./kg per hour. 4. Four C.H.R. u./kg per hour secretin did not increase the output of pepsin. Peptic secretion was stimulated by 8 C.H.R. u./kg per hour. A maximal output of approximately 2000 u. pepsin/15 min was obtained when 16 C.H.R. u./kg per hour was infused. 5. When each acid stimulant was infused along with 4 C.H.R. u./kg per hour secretin the output of pepsin increased significantly. The peak output, which usually occurred between 15 and 30 min after stimulation, did not exceed 1000 u. pepsin/15 min. 6. The proposed explanation for the potentiation of the peptic response when an acid stimulant is infused along with a dose of secretin, in itself below the threshold of peptic stimulation, is that each acid stimulant increases gastric mucosal blood flow, approximately doubling the effective concentration of secretin delivered to the peptic cell.

No abstract